Market Projections for Cocaine Use Disorder Show Promising Growth Through 2036

Cocaine Use Disorder Market Outlook: 2026-2036

The Cocaine Use Disorder (CUD) market is projected to experience remarkable growth during the forecast period spanning from 2026 to 2036. This growth is anticipated to be propelled by several factors, including the emergence of novel therapeutic options, an increase in healthcare accessibility, and a rising incidence of CUD globally.

Current Market Landscape and Emerging Therapies

The recently published report by DelveInsight provides a detailed analysis of the current treatment practices and emerging therapies related to cocaine use disorder. Notable therapies in development include Mavoglurant (STP7; produced by STALICLA), Metyrapone (EMB-001; by Embera NeuroTherapeutics), TMP-301 (developed by Tempero Bio), OMS527 (by Omeros Corporation), and AT-312 (from Astraea Therapeutics). These advancements are crucial as current treatments primarily rely on off-label use of existing medications, with no pharmacological therapies approved by the FDA specifically for CUD at this point.

Market Size and Growth Projections

In 2025, the total market size for CUD across seven major markets (7MM)—which includes the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan—was approximately USD 55 million. Projections indicate that this figure is expected to grow significantly, with a notable compound annual growth rate (CAGR) as we move toward 2036. During this period, the number of diagnosed cases is expected to surge, with estimates indicating approximately 2.48 million cases identified across these markets by 2025, rising further as treatment options become more readily accessible.

Rise in Cocaine Use and Dependence

The increasing prevalence of cocaine consumption is pressing a larger segment of the population to seek diagnosis and treatment. Public awareness around Cocaine Use Disorder is on the rise, enhancing the accessibility of essential healthcare interventions. This development stems from a both a growing acknowledgment of the disorder itself and a push towards better treatment availability. Additionally, the critical lack of approved pharmacological treatments specifically for CUD underlines a significant unmet need within the healthcare community, thus inspiring renewed pharmaceutical interest in innovative therapeutics suitable for managing cocaine dependence.

Advancements in Clinical Research

Moreover, the landscape of clinical research surrounding cocaine use disorder shows promising developments. Investigations into pharmacological solutions targeting craving, relapse prevention, and the neurobiological mechanisms responsible for cocaine dependency are rapidly evolving. Emerging candidate therapies like Mavoglurant, Metyrapone, TMP-301, and others aim to provide tailored treatment avenues, which could potentially reshape the future therapeutic landscape for cocaine use disorder.

Shikha Bhardwaj, Associate Consultant at DelveInsight, notes that recent breakthroughs in understanding the complexities of cocaine addiction have equipped researchers with the tools necessary to develop effective pharmacological interventions for CUD.

Competitive Landscape for Cocaine Use Disorder Treatments

The competition in the cocaine use disorder treatment space is intensifying, with several companies making headway in developing new therapeutics. Mavoglurant, which acts as a selective non-allosteric antagonist of the metabotropic glutamate receptor 5 (mGluR5), stands out as a promising candidate in clinical trials. Proven effective in reducing cocaine cravings with a good safety profile, its progress is bolstered by supportive studies under the National Institute on Drug Abuse (NIDA).

Similarly, EMB-001 combines two different agents to help modulate the body's stress response system, seeking to alleviate cravings and minimize relapse events. Early clinical trials have been promising, though data regarding its late-stage development remains scarce. TMP-301, on the other hand, aims specifically at the glutamatergic pathways related to addiction, and it is designed to proactively combat cravings, an essential aspect of CUD management.

Future Directions

The anticipated approval and market entry of these new therapies are set to dramatically change the cocaine use disorder treatment paradigm. As regulatory bodies assess these innovative solutions, the potential for significant advancements in patient care and overall market growth become increasingly likely. Overall, the outlook for the cocaine use disorder market is one of optimism, emphasizing the continual need for innovation and effective treatment options.

For more comprehensive insights into the evolving landscape of cocaine use disorder therapeutics and market dynamics, visit DelveInsight's detailed report.